Pramipexole

Generic Name: Pramipexole

Brand Names: Mirapex, Mirapexin, Sifrol, Pramipexole Teva, Oprymea

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₇N_₃S

CAS Number: 104632-26-0

Unique Ingredient Identifier: 83619PEU5T

Background: Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is one of the most common neurodegenerative disorders and...

Indication: This drug is indicated for the symptomatic treatment of Parkinson’s disease . This drug can be administered as monotherapy or in conjunction with levodopa. It is also indicated for symptomatic treatment of moderate to severe primary Restless Legs Syndrome (RLS) .

Associated Conditions: Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)

Associated Therapies: -

Clinical Trials

Precision Care for Major Depressive Disorder

Phase 4

Conditions: Major Depressive Disorder
Depression
Depressive Disorder, Major

Interventions: Other: Care as usual (CAU) plan
Behavioral: Complicated Grief Treatment (CGT)
Drug: Pramipexole
Drug: Methylphenidate
Behavioral: Mindfulness-based Stress Sensitivity Therapy (MBSST)
Drug: Phenelzine

First Posted Date: 2024-08-30

Last Posted Date: 2024-10-22

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 150

Registration Number: NCT06580041

Locations: 🇺🇸
Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco, San Francisco, California, United States

Long-term Efficacy of Pramipexole in Anhedonic Depression

Phase 3

Recruiting

Conditions: Anhedonia
Depression

Interventions: Drug: Pramipexole

First Posted Date: 2023-04-24

Last Posted Date: 2024-05-23

Lead Sponsor: Region Skane

Target Recruit Count: 80

Registration Number: NCT05825235

Locations: 🇸🇪
Region Skåne, Lund, Scania, Sweden

Efficacy of Treatment With Pramipexole or Risperidone in Patients With Refractory Obsessive-compulsive Disorder (OCD)

Phase 2

Not yet recruiting

Conditions: Obsessive-Compulsive Disorder

Interventions: Drug: Risperidone
Drug: Pramipexole

First Posted Date: 2022-06-02

Last Posted Date: 2022-06-02

Lead Sponsor: Clinical Academic Center (2CA-Braga)

Target Recruit Count: 52

Registration Number: NCT05401019

Pramipexole for Anhedonic Depression

Phase 3

Recruiting

Conditions: Depression
Psychiatric Disorders Mood
Anhedonia

Interventions: Drug: Placebo
Drug: Pramipexole

First Posted Date: 2022-05-02

Last Posted Date: 2024-05-23

Lead Sponsor: Region Skane

Target Recruit Count: 120

Registration Number: NCT05355337

Locations: 🇸🇪
Region Skåne, Lund, Scania, Sweden

Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy

Phase 4

Recruiting

Conditions: Adrenoleukodystrophy
Restless Legs Syndrome

Interventions: Drug: Placebo
Drug: Pramipexole

First Posted Date: 2021-08-12

Last Posted Date: 2024-04-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 24

Registration Number: NCT05003648

Locations: 🇳🇱
University Medical Center of Amsterdam, Amsterdam, Netherlands
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression

Phase 4

Recruiting

Conditions: Treatment Resistant Depression

Interventions: Drug: Quetiapine
Drug: Amantadine
Drug: Pramipexole

First Posted Date: 2021-06-23

Last Posted Date: 2023-08-22

Lead Sponsor: All India Institute of Medical Sciences, Bhubaneswar

Target Recruit Count: 150

Registration Number: NCT04936126

Locations: 🇮🇳
All India Institute of Medical Sciences, Bhubaneswar, Orissa, India

Treatment of Restless Legs Symptoms With Pramipexole to Improve the Outcomes of Protracted Opioid Withdrawal in OUD

Phase 2

Recruiting

Conditions: Opioid Withdrawal
Sleep Disorder
Restless Legs Syndrome
Opioid-use Disorder

Interventions: Drug: Placebo
Drug: Pramipexole

First Posted Date: 2021-02-18

Last Posted Date: 2024-03-12

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 80

Registration Number: NCT04759703

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Gavin Foundation Clinical Stabilization Services, Quincy, Massachusetts, United States

Social Decision Making in Parkinson's Disease

Phase 1

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexole
Drug: Placebo

First Posted Date: 2020-01-31

Last Posted Date: 2023-10-18

Lead Sponsor: Vanderbilt University Medical Center

Target Recruit Count: 18

Registration Number: NCT04249544

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States

Pramipexole and Morphine for Renal Colic

Phase 1

Completed

Conditions: Renal Colic

Interventions: Drug: Pramipexole
Drug: Placebo oral tablet
Drug: Morphine

First Posted Date: 2019-11-13

Last Posted Date: 2023-03-08

Lead Sponsor: East Carolina University

Target Recruit Count: 19

Registration Number: NCT04160520

Locations: 🇺🇸
Vidant Medical Center ED, Greenville, North Carolina, United States

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Phase 2

Completed

Conditions: Parkinson Disease

Interventions: Drug: KDT-3594
Drug: Pramipexole

First Posted Date: 2019-02-19

Last Posted Date: 2021-02-17

Lead Sponsor: Kissei Pharmaceutical Co., Ltd.

Target Recruit Count: 74

Registration Number: NCT03845387

Locations: 🇯🇵
Research Site, Multiple Locations, Japan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy